Megan Hardin

Jul 1, 2024 | sciencedirect.com | Jorge Maspero |Megan Hardin |Remy S. Petersen |Danny Cohn

Previous randomized controlled trials have established the efficacy of dupilumab among patients with chronic obstructive pulmonary disease (COPD) treated with triple therapy over 52 weeks of follow-up. This population-based cohort study aimed to explore the long-term safety and effectiveness of dupilumab in patients with COPD. The study included US patients with COPD who were seen between April 2017 and August 2024.

Feb 2, 2024 | sciencedirect.com | Leonard B. Bacharier |Megan Hardin |Sameer Bahal |Giorgia Santilli

Section snippetsStudy populationThis study included 811 children from the BBC (ClinicalTrial.gov NCT03228875). The BBC consists of a predominantly urban, underrepresented (59% Black and 22% Hispanic) population residing in low-income communities in the United States. The BBC was initiated in 1998 with rolling enrollment at the Boston Medical Center in Boston. Details about this parent cohort have been reported elsewhere.20 The BBC sample is enriched with preterm births (<37 weeks’ gestation).